U.S. Food And Drug Administration

Higher-dose Exelon patch approved for Alzheimer's care

The U.S. Food and Drug Administration recently approved a higher dose Exelon Patch (rivastigmine transdermal system) for people with mild to moderate Alzheimer's disease.

Alzheimer's scan clears advisory committee

An advisory committee to the U.S. Food and Drug Administration voted unanimously Thursday that the FDA should approve a brain scan that can identify the beta amyloid plaques that characterize Alzheimer's in living persons. The FDA typically follows the advice of the advisory committee.